Novartis secures US rights to Adamis’ epinephrine auto injector

pharmafile | July 3, 2018 | News story | Manufacturing and Production, Sales and Marketing Adamis, Novartis, Symjepi, US, auto injector, pharma 

Novartis has penned an agreement with Adamis Pharmaceuticals to commercialise and distribute the latter’s epinephrine auto injector Symjepi in the US market, it has emerged.

Under the agreement, the Swiss pharma firm will be awarded the rights to the 0.3mg and 0.15mg dosages of the product, subject to FDA approval. The two firms will equally share net profits from the sale of the drug in the US, and Novartis will be eligible to receive milestone payments based on the Symjepi’s performance. As part of the deal, Adamis also paid out an upfront fee, the value of which has not been disclosed.

Adamis retains rights to the drug outside of the US, but Novartis subsidiary Sandoz will have first right of negotiation in these territories.

Symjepi is designed to act as an emergency treatment for allergic reactions, including anaphylaxis. On announcing the deal with Novartis, the San Diego-based manufacturer’s share price rocketed by 40%.

“We are very excited about our collaboration with Sandoz.  They are among the top pharmaceutical companies in the world and we believe they have the commercial presence and proven track record to maximise the value of Symjepi,” commented Dr Dennis J Carlo, President and CEO of Adamis. “We believe the financial terms of this agreement have the potential to bring meaningful recurring revenue to Adamis and we look forward to growing, and possibly expanding, this partnership with Sandoz based on the future success of Symjepi in the market.”

Matt Fellows

Related Content

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa

Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human …


AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard

Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the …

Expansion for first FDA-approved video game for ADHD treatment

Akili Interactive has announced the expansion of its prescription video game treatment, EndeavorRx, with the …

Latest content